More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.
New findings have the potential to significantly benefit the field of neuroscience and could help guide researchers in designing more cost-effective, fruitful studies of the brain.
Are care teams doing enough to take on inflammation? The American Heart Association hopes this new research initiative can help answer that question, and many others.
Former ACC president Kim Allan Williams Sr., MD, thinks cardiologists should be much more proactive. Encouraging healthy eating habits now, for example, can keep patients out of the hospital later in life and reduce healthcare spending.
